A U.S. appeals court has vacated a decision from the U.S. Patent and Trademark Office (USPTO), reviving a spat between Recor Medical and Medtronic. The patent battle centers around renal denervation (RDN) technology for treating hypertension. Recor and Medtronic are the two leaders in this space, with Recor Medical receiving an FDA nod for its Paradise […]
ReCor Medical
Medtronic achieves renal denervation reimbursement milestone with CMS
Medtronic announced that CMS is opening a national coverage analysis on renal denervation (RDN) procedures for patients with hypertension. This process allows the agency to review and develop a national Medicare coverage policy for RDN procedures. CMS initiated the analysis after Medtronic requested beneficiary access support for its Symplicity Spyral RDN system. A national coverage […]
Medtronic, Recor Medical score renal denervation reimbursement wins
Medtronic and Recor Medical each announced separate Medicare reimbursement approvals for their respective renal denervation (RDN) technologies. Going into effect on Jan. 1, 2025, the approvals could increase patient access to the new hypertension treatments. Medtronic secured a Transitional Pass-Through (TPT) payment under the Medicare Hospital Outpatient Prospective Payment System for its Symplicity Spyral renal […]
Medtronic, Recor Medical applaud European support for renal denervation
Medtronic praised new European Society of Cardiology (ESC) 2024 guidelines for renal denervation (RDN) procedures for hypertension. The ESC upgraded renal denervation to a Class IIb recommendation for patients with uncontrolled and resistant hypertension. Officials presented the new guidelines at the ESC Congress on Aug. 30 in London. Medtronic said the new guidelines outline patient […]
Medtronic, Recor Medical earn CMS NTAP wins for renal denervation tech
Medtronic and Recor Medical earned a reimbursement win for their renal denervation (RDN) platforms with a new Final Rule from CMS. CMS posted its FY25 Inpatient Prospective Payment System (IPPS) Final Rule, which includes the New Technology Add-on Payment (NTAP) program. NTAP supports access for newly approved, innovative technologies where the cost to adopt may […]
The top medtech trends of 2023
The top medtech trends of 2023 included innovations such as artificial intelligence, new GLP-1 weight loss drugs and some long-awaited medtech finally receiving regulatory nods. With health providers facing additional challenges on top of an ever-uncertain economic environment, medtech companies also made major readjustments: layoffs, spinoffs, reorganizations and much more. Here are the top stories […]
What’s next for Medtronic’s RDN program after FDA approval?
Medtronic is planning its first commercial renal denervation (RDN) cases and is already running a postmarket study after winning FDA approval of its Symplicity Spyral system for hypertension. In an interview before the Thanksgiving break, Medtronic SVP Jason Weidman — who’s also president of the company’s coronary and RDN business — said he expects the […]
Recor Medical launches renal denervation system, announces first commercial cases
Recor Medical announced the first commercial uses of its Paradise ultrasound renal denervation (uRDN) system for treating hypertension. The first commercial uses follow the company’s landmark FDA approval for Paradise last week. Approval allows for the use of Paradise as an adjunctive treatment option when lifestyle changes and medications fail to control a patient’s blood […]
Recor Medical wins first FDA nod for renal denervation to treat hypertension
Recor Medical announced that the FDA approved its Paradise ultrasound renal denervation (RDN) system for treating hypertension. The long-awaited approval for the Otsuka Medical Devices portfolio company allows for the use of Paradise as an adjunctive treatment option when lifestyle changes and medications fail to adequately control a patient’s blood pressure. Paradise had looked the […]
Recor Medical presents more data supporting its renal denervation system
Otsuka Medical Devices’ Recor Medical announced another set of positive study results for its Paradise ultrasound renal denervation (uRDN) system. A combined analysis of six-month follow-up data from three RADIANCE global studies evaluated Paradise as a hypertension treatment. The analysis demonstrated maintained blood pressure (BP) reduction following treatment with uRDN compared to sham. It also […]
The biggest cardiovascular stories from TCT 2023
Every year, some of the biggest names in cardiovascular technologies come together in one place for TCT. This year’s 35th edition of the Transcatheter Cardiovascular Therapeutics annual scientific symposium was no different in San Francisco. Usual suspects like Medtronic and Abbott released data covering a range of products, while other big names like Edwards, GE […]
